» Articles » PMID: 36644568

Events in CNS Tumor Pathology Post-2016 WHO CNS: CIMPACT-NOW Updates and Other Advancements: A Comprehensive Review Plus a Summary of the Salient Features of 2021 WHO CNS 5

Overview
Journal Int J Gen Med
Publisher Dove Medical Press
Specialty General Medicine
Date 2023 Jan 16
PMID 36644568
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: The 2016 World Health Organization Classification (WHO) of Tumors of the Central Nervous System (CNS) represented a major change. It recommended an "integrated diagnosis" comprising histologic and molecular information facilitating a more precise diagnosis of specific CNS tumors. Its goal was to provide greater diagnostic precision and reproducibility resulting in more clinical relevance and predictive value, ultimately leading to better patient care. Advances in molecular classification, mostly resulting from DNA methylation array profiling of CNS tumors, were occurring at a very rapid pace and required more rapid integration into clinical practice.

Methods: cIMPACT-NOW updates and other recent papers plus salient features of 2021 WHO CNS5 in this comprehensive write-up were reviewed.

Results: CNS tumor classification needs to be updated at a rapid pace and mechanisms put into place to guide diagnosticians and clinicians in the interim period if major changes in the classification of tumor types came to light. Recognizing the need to integrate these into clinical practice more rapidly and without inordinate delay, the International Society of Neuropathology (ISN) 2016 sponsored an initiative called cIMPACT-NOW.

Discussion And/or Conclusion: Goal of cIMPACT-NOW was to provide clarification regarding contentious issues arising in the wake of the 2016 WHO CNS update as well as report new advancements in molecular classification of CNS tumors and new tumor entities emerging as a result of these advancements. cIMPACT-NOW updates: It thus laid the foundation for the 5th edition of the WHO Classification of CNS tumors (2021 WHO CNS 5). We have discussed cIMPACT updates in detail in this review. In addition, molecular diagnostics including DNA methylation-based classification of CNS tumors and the practical use of molecular classification in the prognostication and treatment of CNS tumors is discussed. Finally, the salient features of the new CNS tumor classification are summarized.

Citing Articles

Clinico-Pathological Features of Diffuse Midline Glioma, H3 K27-Altered in Adults: A Comprehensive Review of the Literature with an Additional Single-Institution Case Series.

Broggi G, Salzano S, Failla M, Barbagallo G, Certo F, Zanelli M Diagnostics (Basel). 2024; 14(23).

PMID: 39682526 PMC: 11640674. DOI: 10.3390/diagnostics14232617.


Evolution of Molecular Biomarkers and Precision Molecular Therapeutic Strategies in Glioblastoma.

Jacome M, Wu Q, Pina Y, Etame A Cancers (Basel). 2024; 16(21).

PMID: 39518074 PMC: 11544870. DOI: 10.3390/cancers16213635.


Nanoparticles for efficient drug delivery and drug resistance in glioma: New perspectives.

Liu J, Yang F, Hu J, Zhang X CNS Neurosci Ther. 2024; 30(5):e14715.

PMID: 38708806 PMC: 11071172. DOI: 10.1111/cns.14715.

References
1.
Feldman A, Jennings L, Wadhwani N, Brat D, Horbinski C . The Essentials of Molecular Testing in CNS Tumors: What to Order and How to Integrate Results. Curr Neurol Neurosci Rep. 2020; 20(7):23. DOI: 10.1007/s11910-020-01041-7. View

2.
Cloughesy T, Mochizuki A, Orpilla J, Hugo W, Lee A, Davidson T . Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019; 25(3):477-486. PMC: 6408961. DOI: 10.1038/s41591-018-0337-7. View

3.
Stichel D, Ebrahimi A, Reuss D, Schrimpf D, Ono T, Shirahata M . Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. Acta Neuropathol. 2018; 136(5):793-803. DOI: 10.1007/s00401-018-1905-0. View

4.
Ceccarelli M, Barthel F, Malta T, Sabedot T, Salama S, Murray B . Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell. 2016; 164(3):550-63. PMC: 4754110. DOI: 10.1016/j.cell.2015.12.028. View

5.
Louis D, Perry A, Wesseling P, Brat D, Cree I, Figarella-Branger D . The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021; 23(8):1231-1251. PMC: 8328013. DOI: 10.1093/neuonc/noab106. View